News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Technology used in mRNA COVID vaccines offers hope for treatment of millions with heart disease, study suggests
Combining technologies that proved hugely success against cancer and in COVID-19 vaccines, researchers at Penn have shown they can effectively treat a leading cause of heart disease.
ŌNŌCOR launches ŌNŌ system
PCI startup ŌNŌCOR announced the first-in-human use of their ŌNŌ endovascular retrieval system for the removal of an intracardiac tumor.
Neuralert’s first product receives FDA Breakthrough Designation
Neuralert addresses the problem of late or undetected stroke in hospitalized patients.
Vaccine-like mRNA injection can be used to make CAR T cells in the body
The researchers, whose work is published in Science, demonstrated the new approach with an mRNA preparation that reprograms T cells—a powerful type of immune cell—to attack heart fibroblast cells.
Lessons in resilience: What changes did you make during the pandemic that you’ll keep with you?
These leaders made changes to workplace communication, collaboration and their personal lives.
Faculty Innovators are Celebrated
The 6th annual Celebration of Innovation returned in a hybrid format for 2021 with both attendees and award recipients participating in person and virtually.
Katalin Karikó, PhD, featured on the cover of Newsweek as one of America’s Greatest Disruptors
She was described as being one of the 50 visionaries whose career-long actions have had far-reaching impact.
iECURE partners to develop next-generation liver-targeted lipid nanoparticles with Penn
iECURE announced that it has entered into an exclusive agreement with Penn to develop next-generation lipid nanoparticles (LNP) for liver gene editing applications.
Penn inventors named Heroes of the Year by Time Magazine
Drs. Katalin Kariko and Drew Weissman, inventors of the foundational RNA research that led to the COVID-19 vaccines, are two of researchers named by Time Magazine as their Heroes of the Year 2021.
Scout Bio licenses new Penn technology to help develop gene therapies for pets
Scout Bio, a Philadelphia company developing gene therapies for animal health, has licensed a new kind of technology from the Penn’s gene therapy program.